ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment

por Rivero, Rocio, Esteva, Mónica Inés, Huang, Erya, Colmegna, Leylen, Altcheh, Jaime, Grossmann, Ulrike, Ruiz, Andrés Mariano
Publicado 2023

Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)

por Altcheh, Jaime, Sierra, Victor, Ramirez, Teresa, Pinto Rocha, Jimy José, Grossmann, Ulrike, Huang, Erya, Moscatelli, Guillermo, Ding, Olivia
Publicado 2023

Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina

por Vizcaya, David, Grossmann, Ulrike, Kleinjung, Frank, Zhang, Ruiping, Suzart-Woischnik, Kiliana, Seu, Sandra, Ramirez, Teresa, Colmegna, Leylen, Ledesma, Oscar
Publicado 2021

Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one...

por Altcheh, Jaime, Castro, Luis, Dib, Juan C., Grossmann, Ulrike, Huang, Erya, Moscatelli, Guillermo, Pinto Rocha, Jimy José, Ramírez, Teresa Estela
Publicado 2021